1. Vinpocetine. Altern Med Rev . 2002;7:240-243.
2. Gulyás B, Halldin C, Vas A, et al. [11 C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. J Neurol Sci . 2005;219-223;229-230.
3. Kraus G, Schulz H, Lohmann A. Determination of apovincaminic acid in serum by means of high-performance liquid chromatography. J Chromatogr . 1992;573:323-327. PubMed
4. Karashurov S. The effect of kavinton on bronchial tonus in brachial asthma patients [in Russian]. Eksp Klin Farmakol . 1994;57:35-36. PubMed
5. Burtsev E, Savkov V, Shprakh V, Burtsev M. 10-year experience with using Cavinton in cerebrovascular disorders. Zh Nevropatol Psikhiatr Im S S Korsakova . 1992;92:56-60. PubMed
6. Karpati E, Biro K, Kukorelli T. Investigation of vasoactive agents with indole skeletons at Richter Ltd [in Hungarian]. Acta Pharm Hung . 2002;72:25-36. PubMed
7. Kiss B, Karpati E. Mechanism of action of vinpocetine [in Hungarian]. Acta Pharm Hung . 1996;66:213-224. PubMed
8. Olah VA, Balla G, Balla J, Szabolcs A, Karmazsin L. An in vitro study of the hydroxyl scavenger effect of Cavinton . Acta Paediatr Hung . 1990;30:309-316. PubMed
9. Pereira C, Agostinho P, Moreira P, Duarte A, Santos M, Oliveira C. Neuroprotection strategies: effect of Vinpocetine in vitro Oxidative Stress Models. Acta Med Port . 2003;16:401-406. PubMed
10. Horvath B, Marton Z, Halmosi R, et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol . 2002;25:37-42. PubMed
11. Santos M, Duarte A, Moreira P, Oliveira C. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res . 2000;32:57-66.
12. Gabryel B, Adamek M, Pudelko A, Malecki A, Trzeciak H. Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology . 2002;23:19-31. PubMed
13. Kolarov G, Orbetsova M, Nalbanski B, et al. Complex effects of cavinton on climacteric symptoms. Akush Ginekol . 2001;42:37-41.
14. Kiss E. Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther Hung . 1990;38:170-173.
15. Nosalova V, Machova J, Babulova A. Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung . 1993;43:981-985. PubMed
16. Kovalev I, Baskakov M, Popov A, et al. Studying cGMP-dependent mechanisms of vinpocetine effect on smooth muscle cells [in Russian]. Eksp Klin Farmakol . 2003;66:25-28.
17. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol . 2005;288:L103-L105. PubMed
18. Truss M, Stief C, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol . 2000;18:439-443. PubMed
19. Truss M, Stief C, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol . 2001;19:344-350. PubMed
20. Sitges M, Nekrassov V. Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin Neurophysiol . 2004;115:2711-2717. PubMed
21. Maliavina US, Ovchinnikov IUM, Fasenko VP, Maliev BM, Kalinina MV, Dadasheva BB. Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis [in Russian]. Vestn Otorinolaringol . 2003;(3):35-40. PubMed
22. Sitges M, Galvan E, Nekrassov V. Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int . 2005;46:533-540. PubMed
23. Dutov AA, Tolpyshev BA, Karpov VN, Petrov AP. Effect of Cavinton on convulsions caused by chemical substances [in Russian]. Farmakol Toksikol . 1986;49:22-25. PubMed
24. Nekrassov V, Sitges M. Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res . 2004;60:63-71. PubMed
25. Dutov AA, Tolpyshev BA, Petrov AP, Gladun VN. Use of cavinton in epilepsy [in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova . 1986;86:850-855. PubMed
26. Dutov AA, Gal'tvanitsa GA, Volkova VA, Sukhanova ON, Lavrishcheva TG, Petrov AP. Cavinton in the prevention of the convulsive syndrome in children after birth injury [in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova . 1991;91:21-22. PubMed
27. Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J Am Geriatr Soc . 1989;37:515-520. PubMed
28. Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol . 1985;28:567-571. PubMed
29. Otroshchenko N. Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident [in Russian]. Lik Sprava . 2000;September:8-10. PubMed
30. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol . 1991;6:31-43. PubMed
31. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev . 2003;(1):CD003119. PubMed
32. Dezsi L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E. Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke [in Hungarian]. Acta Pharm Hung . 2002;72:84-91. PubMed
33. Yasui M, Yano I, Ota K, Oshima A. Contents of calcium, phosphorus and aluminum in central nervous system, liver and kidney of rabbits with experimental atherosclerosis – scavenger effects of vinpocetine on the deposition of elements. No To Shinkei . 1990;42:325-331. PubMed
34. Hayakawa M. Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimittelforschung . 1992;42:425-427. PubMed
35. Hayakawa M. Effect of vinpocetine on red blood cell deformability in vivo measured by a new centrifugation method. Arzneimittelforschung . 1992;42:281-283. PubMed
36. Hayakawa M. Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung . 1992;42:108-110. PubMed
37. Gulyas B, Bonoczk P, Vas A, et al. The effect of a single-dose intravenous vinpocetine on brain metabolism in patients with ischemic stroke [in Hungarian]. Orv Hetil . 2001;March 4:142:443-449. PubMed
38. Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol . 2001;8:81-85. PubMed
39. Bonoczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound . 2002;15:85-91. PubMed
40. Szakall S, Boros I, Balkay L, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging . 1998;8:197-204. PubMed
41. Szilagyi G, Nagy Z, Balkay L, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci . 2005;229-230:275-284. PubMed
42. Erdo SL, Molnár P, Lakics V, Bence J, Tömösközi Z. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. Eur J Pharmacol . 1996;314:69-73. PubMed
43. Bonoczk P, Gulyas B, Adam-Vizi V, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull . 2000;53:245-254. PubMed
44. Vas A, Gulyas B, Szabo Z, et al. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci . 2002;203-204:259-262. PubMed
45. Burtsev E, Tugutov A. Therapeutic effect of cavinton in chronic cerebral circulatory insufficiency. Zh Nevropatol Psikhiatr Im S S Korsakova . 1985;85:53-56. PubMed
46. Ishchenko M, Shkrobot S. Effect of cavinton on systemic and cerebral hemodynamics of patients with chronic cerebral circulatory insufficiency. Zh Nevropatol Psikhiatr Im S S Korsakova . 1985;85:1338-1342. PubMed
47. Szapary L, Horvath B, Alexy T, et al. Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease [in Hungarian]. Orv Hetil . 2003;144:973-978. PubMed
48. Burtsev E, Shprakh V, Savkov V. Effectiveness of using cavinton in patients of different ages with chronic forms of cerebrovascular diseases (clinico-rheographic research) [in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova . 1988;88:39-44. PubMed
49. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc . 1987;35:425-430. PubMed
50. Akopov SE, Gabrielian ES. Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. Eur J Clin Pharmacol . 1992;42:257-259. PubMed
51. Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol . 1990;28:323-328. PubMed
52. Lohmann A, Dingler E, Sommer W, Schaffler K, Wober W, Schmidt W. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung . 1992;42:914-917. PubMed
53. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol . 1987;2:325-331. PubMed
54. Hitzenberger G, Schmid R, Braun W, Grandt R. Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int J Clin Pharmacol Ther Toxicol . 1990;28:99-104. PubMed
55. Molnar P, Erdo S. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol . 1995;273:303-306. PubMed
56. Miskolczi P, Kozma K, Polgar M, Vereczkey L. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet . 1990;15:1-5. PubMed
57. Pudleiner P, Vereczkey L. Study on the absorption of vinpocetine and apovincaminic acid. Eur J Drug Metab Pharmacokinet . 1993;18:317-321. PubMed
58. Yao JH, Su CY, Chu XY. Pharmacokinetics and disposition of vinpocetine in rats [in Chinese]. Yao Xue Xue Bao . 1994;29:81-85. PubMed
59. Szakacs T, Veres Z, Vereczkey L. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol J Pharmacol . 2001;53:623-628. PubMed